<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360891</url>
  </required_header>
  <id_info>
    <org_study_id>2012-50</org_study_id>
    <secondary_id>2013-A00969-36</secondary_id>
    <nct_id>NCT02360891</nct_id>
  </id_info>
  <brief_title>Study of Predictive Factors of Progression of Motor Neurone Disease</brief_title>
  <acronym>PULSE</acronym>
  <official_title>Study of Predictive Factors of Progression of Motor Neurone Disease Prognosis and Endophenotype Biomarkers French Database Set up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a complex polymorph and devastating neurodegenerative&#xD;
      disease. Although the pathophysiological mechanisms underlying the development of ALS remain&#xD;
      to be fully elucidated, there have been significant advances in the understanding of ALS&#xD;
      pathogenesis, with evidence emerging of a complex interaction between genetic factors and&#xD;
      dysfunction of vital molecular pathways. However, the numerous randomized clinical trials&#xD;
      (RCT) for ALS have failed to generate improved drug treatments. Biomarkers able to bring&#xD;
      prognostic value and to distinguish the different endophenotypes of this polymorphic disease&#xD;
      could help to better select clusters of patients in order to improve the RCT outcomes.&#xD;
      However, little progress has been made in the development of viable diagnostic, prognostic&#xD;
      and monitoring markers. This could be explained by common shortcomings, such as relatively&#xD;
      small sample sizes, statistically underpowered study designs, lack of disease controls and&#xD;
      poorly characterized patient cohorts. It is yet crucial that the investigators further&#xD;
      develop and validate ALS biomarkers and incorporate these biomarkers into the drug&#xD;
      development pipeline for ALS.&#xD;
&#xD;
      The aim of the present study is therefore to determine the clinical, biological, imaging, and&#xD;
      electrophysiological biomarkers of prognosis of survival without events (i.e. severe&#xD;
      comorbidity, 24 hours of non invasive ventilation, tracheotomy). This is a prospective&#xD;
      observational multicentric French study of a cohort of 1000 ALS patients.&#xD;
&#xD;
      This large multimodal database will be open for international fruitful scientific&#xD;
      collaborations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational multicentric French study of a cohort of 1000 ALS&#xD;
      patients, 100 neurological controls and 200 healthy controls followed from the first signs to&#xD;
      the end of the disease.&#xD;
&#xD;
      The aim of the present study is therefore to determine the clinical, biological, imaging, and&#xD;
      electrophysiological biomarkers of prognosis of survival without events (i.e. severe&#xD;
      comorbidity, 24 hours of non invasive ventilation, tracheotomy).&#xD;
&#xD;
      Secondary objectives will notably include i) the biomarkers of disease progression ii)&#xD;
      biomarkers of diagnosis as compared with controls iii) the determination of the different&#xD;
      endophenotypes according to the prognosis, the genetic profiles and the initial clinical&#xD;
      presentations. Criteria of assessment will notably include detailed medical history, habitus,&#xD;
      past and present treatments, vascular risk factors, ALSFRS-R, muscular testing, respiratory&#xD;
      parameters including early nocturnal saturation and apneal profile, the detailed and&#xD;
      predetermined clinical presentations, extensive cognitive and behavioral examination,&#xD;
      extensive blood, cerebrospinal fluid, urines biological tests, genetic analyses, multiple&#xD;
      brain and spinal MRI sequences, and electrophysiological tests (i.e. electromyogram, MUNIX,&#xD;
      triple stimulation). Invasive tests will be optional (i.e. lumbar puncture, skin biopsies,&#xD;
      muscular biopsies).&#xD;
&#xD;
      The large number of patients will allow in depth statistical analyses, notably to establish&#xD;
      decisional trees (CHAID).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2015</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Change of biomarkers of survival</measure>
    <time_frame>From date of randomization until the date of first documented progression , assessed up to 100 months</time_frame>
    <description>The predictive value of the clinical, biological, imaging, and electrophysiological biomarkers of survival will be analyzed according to the life duration (months) without events (i.e. severe comorbidity, 24 hours of non invasive ventilation, tracheotomy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of biomarkers of disease progression</measure>
    <time_frame>baseline, 3 months, 6 months, 9 months, 12 months, 15 months, 24 months, 36 months, 48 months (average)</time_frame>
    <description>The predictive value of the clinical, biological, imaging, and electrophysiological biomarkers of prognosis will be analyzed according to the rate of progression of the ALSFRS-R score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical endophenotypes according to the survival duration</measure>
    <time_frame>From date of randomization until the date of death related with ALS or tracheotomy or continuous non invasive ventilation (24 hours a day), whichever came first, assessed up to 100 months</time_frame>
    <description>The determination of the different clinical, biological, radiological and electrophysiological endophenotypes (clusters of the same characteristics) according to the survival duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic endophenotypes</measure>
    <time_frame>the date of death related with ALS or tracheotomy or continuous non invasive ventilation (24 hours a day), whichever came first, assessed up to 100 months</time_frame>
    <description>the determination of the different clinical, biological, radiological and electrophysiological endophenotypes (clusters of the same characteristics) according to the according to the genetic forms (SOD1, TDP43, FUS, C9orf72,...)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Motor Neuron Disease</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <description>follow up of patients with amyotrophic lateral sclerosis from the first signs to the end of the disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neurological controls</arm_group_label>
    <description>patients with other neurological disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>age matched healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biomarkers (composite analysis)</intervention_name>
    <description>biological, imaging, electrophysiological and anatomopathological examinations</description>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>neurological controls</arm_group_label>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, white cells, platelets, cerebrospinal fluid,skin, muscle, brains&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Multicentric French cohort of 1000 ALS patients, 100 neurological controls and 200 healthy&#xD;
        controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for ALS patients:&#xD;
&#xD;
          -  Patients with suspicion of Amyotrophic lateral sclerosis&#xD;
&#xD;
          -  Since the first signs (cramps fasciculation) or first deficit at the diagnosis work up&#xD;
&#xD;
          -  Patient older than 18 years&#xD;
&#xD;
          -  Patient able to provide informed consent&#xD;
&#xD;
        Inclusion Criteria for healthy controls:&#xD;
&#xD;
          -  Subjects older than 18 years (matched population for age and sex with ALS)&#xD;
&#xD;
          -  Neurological testing and examination showing no neurological disorders.&#xD;
&#xD;
          -  Not having severe disease or life- functional prognosis&#xD;
&#xD;
        Inclusion Criteria for neurological controls:&#xD;
&#xD;
          -  Patients having a typical neurodegenerative diseases other than ALS (Parkinson's&#xD;
             disease, Alzheimer's disease)&#xD;
&#xD;
          -  Not having severe disease or life- functional prognosis&#xD;
&#xD;
          -  Patient older than 18 years (matched population for age and sex with ALS)&#xD;
&#xD;
          -  Patient able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects younger than 18 years&#xD;
&#xD;
          -  Patient unable to provide informed consent&#xD;
&#xD;
          -  Having severe disease or life- functional prognosis&#xD;
&#xD;
          -  Contraindications MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Devos, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Devos, MD, PhD</last_name>
    <email>david.devos@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominique Maugin, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fausto Viader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nathalie Guy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU, Hôpital Salengro</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Devos, MD, PhD</last_name>
      <email>david.devos@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>David Devos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Couratier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emilien Bernard, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM,Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Attarian Shahram, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Camu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet 1, CHU</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié (AP-HP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François Salachas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Saint Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yvan Kolev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Christophe Antoine, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Corcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multimodal biomarkers</keyword>
  <keyword>prognosis</keyword>
  <keyword>endophenotypes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

